BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 27697594)

  • 1. Drug repurposing for glioblastoma based on molecular subtypes.
    Chen Y; Xu R
    J Biomed Inform; 2016 Dec; 64():131-138. PubMed ID: 27697594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards precision medicine-based therapies for glioblastoma: interrogating human disease genomics and mouse phenotypes.
    Chen Y; Gao Z; Wang B; Xu R
    BMC Genomics; 2016 Aug; 17 Suppl 7(Suppl 7):516. PubMed ID: 27557118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translational validation of personalized treatment strategy based on genetic characteristics of glioblastoma.
    Oh YT; Cho HJ; Kim J; Lee JH; Rho K; Seo YJ; Choi YS; Jung HJ; Song HS; Kong DS; Seol HJ; Lee JI; Yoon Y; Kim S; Nam DH; Joo KM
    PLoS One; 2014; 9(8):e103327. PubMed ID: 25084005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New insights for precision treatment of glioblastoma from analysis of single-cell lncRNA expression.
    Meng Q; Zhang Y; Li G; Li Y; Xie H; Chen X
    J Cancer Res Clin Oncol; 2021 Jul; 147(7):1881-1895. PubMed ID: 33693962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients.
    Wang Z; Wang Y; Yang T; Xing H; Wang Y; Gao L; Guo X; Xing B; Wang Y; Ma W
    Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33839757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs.
    Jiang P; Mukthavaram R; Chao Y; Bharati IS; Fogal V; Pastorino S; Cong X; Nomura N; Gallagher M; Abbasi T; Vali S; Pingle SC; Makale M; Kesari S
    J Transl Med; 2014 Jan; 12():13. PubMed ID: 24433351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
    Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
    Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An integrative characterization of recurrent molecular aberrations in glioblastoma genomes.
    Sintupisut N; Liu PL; Yeang CH
    Nucleic Acids Res; 2013 Oct; 41(19):8803-21. PubMed ID: 23907387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MPC1 deletion is associated with poor prognosis and temozolomide resistance in glioblastoma.
    Chai Y; Wang C; Liu W; Fan Y; Zhang Y
    J Neurooncol; 2019 Sep; 144(2):293-301. PubMed ID: 31236818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integration of RNA-Seq and proteomics data identifies glioblastoma multiforme surfaceome signature.
    Syafruddin SE; Nazarie WFWM; Moidu NA; Soon BH; Mohtar MA
    BMC Cancer; 2021 Jul; 21(1):850. PubMed ID: 34301218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development.
    Brown KE; Chagoya G; Kwatra SG; Yen T; Keir ST; Cooter M; Hoadley KA; Rasheed A; Lipp ES; Mclendon R; Ali-Osman F; Bigner DD; Sampson JH; Kwatra MM
    J Neurochem; 2015 Jun; 133(5):730-8. PubMed ID: 25598002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiogenomic mapping of edema/cellular invasion MRI-phenotypes in glioblastoma multiforme.
    Zinn PO; Mahajan B; Sathyan P; Singh SK; Majumder S; Jolesz FA; Colen RR
    PLoS One; 2011; 6(10):e25451. PubMed ID: 21998659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-wide methylomic and transcriptomic analyses identify subtype-specific epigenetic signatures commonly dysregulated in glioma stem cells and glioblastoma.
    Pangeni RP; Zhang Z; Alvarez AA; Wan X; Sastry N; Lu S; Shi T; Huang T; Lei CX; James CD; Kessler JA; Brennan CW; Nakano I; Lu X; Hu B; Zhang W; Cheng SY
    Epigenetics; 2018; 13(4):432-448. PubMed ID: 29927689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype.
    Teng J; Hejazi S; Hiddingh L; Carvalho L; de Gooijer MC; Wakimoto H; Barazas M; Tannous M; Chi AS; Noske DP; Wesseling P; Wurdinger T; Batchelor TT; Tannous BA
    Neuro Oncol; 2018 Apr; 20(5):642-654. PubMed ID: 29099956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth factor independence underpins a paroxysmal, aggressive Wnt5a
    Trivieri N; Visioli A; Mencarelli G; Cariglia MG; Marongiu L; Pracella R; Giani F; Soriano AA; Barile C; Cajola L; Copetti M; Palumbo O; Legnani F; DiMeco F; Gorgoglione L; Vescovi AL; Binda E
    J Exp Clin Cancer Res; 2022 Apr; 41(1):139. PubMed ID: 35414102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current Challenges and Opportunities in Treating Glioblastoma.
    Shergalis A; Bankhead A; Luesakul U; Muangsin N; Neamati N
    Pharmacol Rev; 2018 Jul; 70(3):412-445. PubMed ID: 29669750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug Repurposing for Glioblastoma and Current Advances in Drug Delivery-A Comprehensive Review of the Literature.
    Alomari S; Zhang I; Hernandez A; Kraft CY; Raj D; Kedda J; Tyler B
    Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mir-21-Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact.
    Sathyan P; Zinn PO; Marisetty AL; Liu B; Kamal MM; Singh SK; Bady P; Lu L; Wani KM; Veo BL; Gumin J; Kassem DH; Robinson F; Weng C; Baladandayuthapani V; Suki D; Colman H; Bhat KP; Sulman EP; Aldape K; Colen RR; Verhaak RG; Lu Z; Fuller GN; Huang S; Lang FF; Sawaya R; Hegi M; Majumder S
    J Neurosci; 2015 Nov; 35(45):15097-112. PubMed ID: 26558781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A combinatorial radiographic phenotype may stratify patient survival and be associated with invasion and proliferation characteristics in glioblastoma.
    Rao A; Rao G; Gutman DA; Flanders AE; Hwang SN; Rubin DL; Colen RR; Zinn PO; Jain R; Wintermark M; Kirby JS; Jaffe CC; Freymann J;
    J Neurosurg; 2016 Apr; 124(4):1008-17. PubMed ID: 26473782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovering gene-environment interactions in glioblastoma through a comprehensive data integration bioinformatics method.
    Kunkle B; Yoo C; Roy D
    Neurotoxicology; 2013 Mar; 35():1-14. PubMed ID: 23261424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.